» Articles » PMID: 25348957

SREBP-1 is a Novel Mediator of TGFβ1 Signaling in Mesangial Cells

Overview
Journal J Mol Cell Biol
Specialty Molecular Biology
Date 2014 Oct 29
PMID 25348957
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Glomerular matrix accumulation is a hallmark of diabetic nephropathy. Recent studies showed that overexpression of the transcription factor SREBP-1 induces glomerulosclerosis. TGFβ1 is a key profibrotic mediator of glomerulosclerosis, but whether SREBP-1 regulates its effects is unknown. In kidney mesangial cells and in vivo, TGFβ1 activates SREBP-1. This requires SCAP, S1P, and PI3K/Akt signaling, but is independent of Smad3. Activation of the TGFβ1-responsive reporter plasmid p3TP-lux requires SREBP-1a, but not SREBP-1c, binding to an E-box adjacent to a Smad-binding element. SREBP-1a overexpression alone activates p3TP-lux. Smad3 is required for SREBP-1a transcriptional activation and TGFβ1 induces association between the two transcription factors. SREBP-1a K333 acetylation by the acetyltransferase CBP is required for Smad3 association and SREBP-1 transcriptional activity, and is also required for Smad3 transcriptional activity. Thus, both Smad3 and SREBP-1a activation cooperatively regulate TGFβ transcriptional responses. SREBP-1 inhibition provides a novel therapeutic strategy for diabetic kidney disease.

Citing Articles

The role of the farnesoid X receptor in diabetes and its complications.

Zhang S, Zhang D, Xu K, Huang X, Chen Q, Chen M Mol Cell Biochem. 2024; .

PMID: 39576464 DOI: 10.1007/s11010-024-05162-2.


Fatty acid metabolism constrains Th9 cell differentiation and antitumor immunity via the modulation of retinoic acid receptor signaling.

Nakajima T, Kanno T, Ueda Y, Miyako K, Endo T, Yoshida S Cell Mol Immunol. 2024; 21(11):1266-1281.

PMID: 39187636 PMC: 11528006. DOI: 10.1038/s41423-024-01209-y.


Podocytopathies associated with familial partial lipodystrophy due to LMNA variants: report of two cases.

Morguetti M, de Menezes Neves P, Korkes I, Padilha W, Jorge L, Watanabe A Arch Endocrinol Metab. 2024; 68:e230204.

PMID: 38739524 PMC: 11156176. DOI: 10.20945/2359-4292-2023-0204.


SREBPs as the potential target for solving the polypharmacy dilemma.

Wang X, Chen Y, Meng H, Meng F Front Physiol. 2024; 14:1272540.

PMID: 38269061 PMC: 10806128. DOI: 10.3389/fphys.2023.1272540.


Extracellular Vesicles Secreted by TGF-1-Treated Mesenchymal Stem Cells Promote Fracture Healing by SCD1-Regulated Transference of LRP5.

Zhou Z, Guo C, Sun X, Ren Z, Tao J Stem Cells Int. 2023; 2023:4980871.

PMID: 36970598 PMC: 10033213. DOI: 10.1155/2023/4980871.